Vishay Intertechnology, Inc. (NYSE: VSH) — A Commodity-Components Cycle Repriced as an AI Supercycle

Independent equity research note. Report date: 2026-06-27. Price reference: $56.35 (2026-06-26 close).

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The analytical body that follows takes no position and carries no price target; only this block does.

Verdict: AVOID at $56 — not a short. Accumulate only on a deep pullback into the high-$20s–mid-$30s. “Great story, wrong price.” Fair-value zone roughly $30–42 (≈8–9x a credible mid-cycle EBITDA of ~$600–750M, net of ~$0.6B net debt), versus $56.35 today — i.e., the stock is discounting roughly 40–50% more than a base-case business is worth. Conviction: medium.

Vishay is a real, recovering, but no-moat, sub-scale, price-taking maker of commodity discrete semiconductors and passive components that has just tripled in a single quarter (≈$18 → $69 → $56) on an AI-and-electrification narrative. The numbers do not support the price: it earns ~19% gross margins (half-to-a-third of TI/onsemi/Infineon), peak-cycle ROIC of only ~17% and negative at the trough, and is burning free cash (–$88M FY25, guided negative again in 2026) on a $1.3B+ capacity build into a still-soft, oversupplied market. At $56 the market pays ~27x trough EBITDA — about 10x the company’s all-time-record FY22 EBITDA — and a richest-ever multiple on every valid metric (composite 99th percentile of its own decade; EV/EBITDA never exceeded ~12x before, now ~27x). To make that price ordinary, Vishay must hit its explicitly “delayed” 2028 plan (revenue $5.5B, 31% gross margin, 20% operating margin, ~$5 EPS) and ride the cycle to a fresh peak — simultaneously, with no margin of safety. The framing is unambiguous from the tape: a crowded, high-beta (β≈2.0) momentum trade that has begun to roll over (–13% off the high, factor alpha just turned negative) — not a falling knife. What keeps me off the short side and respectful of the long-term story: the cyclical trough is genuinely behind it (book-to-bill 1.34, backlog +21%), the electrification/defense content tailwinds are real, and — the single best bull tell — the CEO, CFO, COO and several directors bought the open-market bottom with personal cash at $14–16 in May 2025 and have not sold a share into the rip.

Framing: crowded-momentum / narrative-driven re-rate of a cyclical price-taker, now stalling. Bull trigger that would flip me constructive: gross margin climbing durably through the mid-/high-20s with FCF turning positive — proof the Vishay 3.0 margin step-up is structural, not an aspiration. Bear trigger that would flip me negative outright: book-to-bill back below 1.0 or margins stuck in single digits while the AI narrative cracks — at β≈2.0 the unwind would be violent. Tag: “Ten times its best year ever, on its worst earnings.”

📈 Stock Price Action — Five-Year Event Map

Text-only price history (no chart rendered). Price moves are FACT; attributed drivers are INTERPRETATION. No recommendation, no price target — the opportunity judgment lives in Claude’s Take above.

The arc. Over five years VSH did almost nothing, then went vertical. From ~$20 in mid-2021 the stock bled to a five-year closing low of $10.28 (2026-04-08; intraday $10.07) across a full components up-and-down cycle — then, in ~10 weeks, it tripled: from a $17.97 close on 2026-03-31 to a five-year closing high of $64.90 (2026-06-18; intraday $69.47), before fading to $56.35. That is ~5.5x off the April-2025 low and ~13% below the closing high (~19% below the intraday high). The 52-week range is $11.60–$69.47; the 200-day EMA sits near $28 — price is ~2x above its own one-year trend.

Narrative. (1–2) VSH printed all-time-record revenue ($3.50B) and EBITDA (~$779M) in FY22 yet never re-rated — the market read the cyclical peak correctly and held the multiple at a normal ~3.6–4.5x EV/EBITDA. (3) The genuine trough — FY24 loss, FY25 op margin 1.85%, two years of negative free cash flow as Vishay 3.0 capex outran a depressed P&L — drove the stock to a decade low, ~0.46x sales. (4) It doubled off the low to ~$18 on ordinary cyclical recovery. (5) The Q1-26 call reframed VSH from “cyclical recovery” to “secular AI story.” (6–7) The narrative then met a momentum/ETF bid and added ~50% in two weeks on no new disclosure, peaking 2026-06-18 — a move that was overwhelmingly multiple expansion (trailing EBITDA was flat-to-down throughout). (8) Momentum has since cooled and factor alpha turned negative — the first sign the one-way move stalled.

1. Executive Summary

Vishay Intertechnology is a broad-line, vertically integrated manufacturer of the cheapest, most numerous, most substitutable parts on a circuit board — discrete semiconductors (MOSFETs, diodes, optoelectronics; 47% of revenue) and passive components (resistors, inductors, capacitors; 53%). It is a deeply cyclical industrial, not a secular-growth franchise: revenue has oscillated in a $2.5–3.5B band for a decade with no trend, peaking at $3.50B in FY22 and falling to net losses in FY24 (–$0.23) and FY25 (–$0.07). A cyclical recovery is genuinely underway — Q1-26 revenue $839M (+17% YoY), book-to-bill 1.34, backlog +21% to $1.6B — but margins remain trough-level (Q1-26 operating margin 2.6%, gross margin 21%).

The investment tension is entirely about price, not whether the business is recovering. On the strength of an AI-data-center-and-electrification narrative, the stock has tripled in a single quarter to $56, a richest-ever valuation on every valid metric: EV/EBITDA ~27x (versus a decade band of 3.6–11.8x that never once exceeded 12x), EV/sales ~2.6x (versus ~0.7–1.1x), P/S 2.4x and P/TBV ~4.6x — the AZI composite own-history percentile is the 99th. Expressed cleanly: the market is paying ~10.6x Vishay’s all-time-record FY22 EBITDA for a business currently generating one-third of that and negative free cash flow.

The business does not earn that multiple. Vishay has no durable competitive advantage — it is a #2–#4 price-taker against larger, better-capitalized rivals (Infineon, onsemi, STMicro in power semis; Murata, TDK, Yageo in passives), with gross margins half-to-a-third of theirs, peak-cycle ROIC of only ~17% and negative returns at the trough. Its forward plan — “Vishay 3.0” — is a $1.3B+, deficit-funded capacity build (German 12-inch fab, Newport wafer fab) into a still-oversupplied market, the textbook negative-capital-cycle signature, producing negative free cash flow three years running and funding even the modest dividend with borrowing. The aspirational 2028 targets (revenue $5.5B, 31% gross margin, 20% operating margin, ~$5 EPS) sit above anything the company has ever achieved and management already concedes they are “delayed.”

Embedded-expectations analysis shows no margin of safety: to make today’s enterprise value an ordinary 8x EBITDA, Vishay must reach ~$1.0B of EBITDA — ~1.3x its record — i.e., hit the full delayed 2028 plan and a cyclical peak at once. A base (mid-cycle) outcome still leaves the stock above its historical valuation ceiling; only the full-bull case makes $56 a normal multiple. The countervailing evidence is real and keeps this off the short side: the trough has passed, electrification/defense content growth and the Nexperia share gift are genuine, and management bought the open-market bottom heavily in May 2025 and has not sold into the rally. The body that follows takes no position; it lays out the evidence on which the (separately fenced) author’s view rests.

2. Business Overview

What it is. Vishay Intertechnology is a broad-line manufacturer of discrete electronic components — both semiconductors (MOSFETs, diodes, optoelectronics) and passive components (resistors, inductors, capacitors). These are the low-level “DNA” parts that sit on virtually every printed circuit board: a MOSFET switches power, a diode rectifies or protects, a resistor regulates current, a capacitor stores charge. They are sold by the billions of units at unit prices typically measured in cents. Vishay does not sell systems, software, or subsystems; it sells the cheapest, most numerous, most substitutable layer of the bill of materials. (FACT — 10-K Item 1, “Products.”)

The six reportable segments (FY2025 net revenues, % of $3,069.0M total, and segment gross margin): (FACT — 10-K Note 15)

Note the $371.8M of segment operating income is before $314.9M of unallocated corporate SG&A, which leaves consolidated operating income of just $56.9M (1.9% margin) — see Note 15 reconciliation. (FACT — 10-K Note 15.)

Semis vs. passives. Passive components (Resistors + Inductors + Capacitors) were $1,629.3M = 53.1% of FY25 revenue; semiconductors (MOSFETs + Diodes + Optoelectronics) were $1,439.8M = 46.9%. (FACT — derived from Note 15.) The split matters: the passive side is the better business (Resistors/Inductors/Capacitors all ran 21–28% gross margin and double-digit op margins), while the semiconductor side is the drag — MOSFETs alone lost money at the segment level (–$30.6M) on a 9.8% gross margin and consumed $182.4M of the company’s $273.3M total capex (67%). (FACT — Note 15.) The market’s “AI/power-semiconductor” narrative (the reason the stock tripled) is pointed squarely at the company’s worst-returning, most capital-hungry segment.

Product mix. By type: commodity 26%, certified 48%, custom 26% of FY25 revenue. (FACT — 10-K “Products.”) Only ~25% of revenue comes from products developed in the previous five years — and even less in the cash-cow lines (Diodes 20%, Resistors 20%, Inductors not disclosed but mature). (FACT — 10-K.) This is a portfolio of legacy catalog parts, not a stream of new design wins.

End-market split (FY2025, Note 15): (FACT)

• Automotive — $1,088.1M (35.5%) — largest end market.
• Industrial — $1,064.4M (34.7%).
• Military & Aerospace — $314.1M (10.2%) — the one growing end market (up from $271.9M in FY23).
• Healthcare — $152.1M (5.0%).
• “Other” (power supplies, telecom, consumer, computing) — $450.4M (14.7%) — the most cyclical bucket; this is where any “AI data-center” revenue lands today.

Auto + Industrial = ~70% of revenue, both deeply cyclical, both still working off the 2024–25 components inventory glut.

Channel mix (by customer type, FY2025): (FACT — Note 15)

• Distributors — $1,716.2M (55.9%) — the majority of sales go through catalog/franchise distributors (Avnet, TTI, WPG, Wuerth, etc.) who hold inventory for resale. This is significant: distribution revenue is the most volatile (it amplifies the inventory cycle — distis over-order in upcycles and de-stock violently in downcycles), and Vishay recognizes revenue on a “sold-to” basis with scrap/price-protection/“ship-and-debit” credits that introduce estimation risk. (FACT — 10-K Revenue Recognition.)
• OEMs — $1,147.0M (37.4%).
• EMS companies — $205.8M (6.7%).

Customer concentration: Top-30 customers ≈ 74% of revenue; no single customer >10% of consolidated revenue, though certain subsidiaries/product lines do have >10% single-customer exposure, and one customer was 12.8% of the year-end A/R balance. (FACT — 10-K Item 1 and Note 15.)

Geographic mix (by customer region, FY2025): Asia $1,294.9M (42.2%), Europe $1,028.1M (33.5%), Americas $746.1M (24.3%). (FACT — Note 15.) By production location, Germany ($904.2M of subsidiary revenue) and the U.S. ($768.1M) are the largest manufacturing bases. 22,600 full-time employees — heavily China (6,900), Germany (2,300), U.S. (2,100), Israel (2,000), Taiwan (1,900). (FACT — 10-K Item 1.) This is a labor- and capital-heavy, vertically integrated manufacturer — it owns wafer fabs (Newport UK, Itzehoe Germany under construction, Taiwan, Italy) — not a fabless designer.

How it makes money. Vishay earns a spread between component selling prices and a manufacturing cost base dominated by raw materials, direct labor, and depreciation on its owned fabs/assembly. R&D was $122.4M (4.0% of revenue) in FY25 — low for “semiconductors,” appropriate for a commodity-component maker. (FACT — 10-K Note 1.) Earnings are almost entirely a function of (a) volume (units shipped), (b) average selling price (ASP, structurally declining), and © capacity utilization (fixed-cost absorption). There is no meaningful recurring/contracted revenue: orders are placed against customer forecasts, backlog is cancellable without penalty, and the model is transactional and cyclical, not recurring. (FACT — 10-K “Backlog.”)

Verdict (§7.1). Vishay is a sub-scale, vertically integrated, broad-line commodity-component maker — a hybrid of a mediocre discrete-semiconductor business (MOSFETs/diodes/opto, ~47% of revenue, the loss-making and capex-hungry half) and a respectable-but-unexciting passive-components business (resistors/inductors/capacitors, ~53%, the cash engine). Revenue is transactional, ~56% intermediated through volatile distribution, ~70% tied to cyclical auto/industrial demand, and ~75% derived from products older than five years. It makes money on volume × price × utilization, and it is currently emerging from a trough in which the consolidated business barely broke even. This is a cyclical industrial, not a secular growth franchise — a fact the §7.1 numbers establish before we even reach the moat question.

3. Industry Dynamics

Industry structure: fragmented, commoditized, and capital-intensive — the worst of three worlds. The discrete-semiconductor and passive-component industry is one of the structurally least attractive corners of the broad semiconductor complex. Three features define it:

1. Commoditization and price erosion. Vishay itself classifies only 26% of revenue as “commodity,” but the reality is harsher: even “certified” parts (48%) are second-sourced by design — customers deliberately qualify multiple vendors so that no single supplier has pricing power. The industry’s defining long-run characteristic is falling ASPs: prices decline ~1–3% per year in normal markets, and even in the current recovery (Q1-26 revenue +17% YoY, book-to-bill 1.34) management has flagged ASPs roughly flat-to-down (~–1%). (FACT — seeded transcript/log; INTERP — long-run ASP erosion is the structural norm for discrete/passive components.) A business where the unit price falls every year must grow units faster than price falls merely to stand still — and Vishay’s revenue has not: it has oscillated in a $2.5–3.5B band for a decade (FY18 $3,035M → FY22 peak $3,497M → FY25 $3,069M), i.e., no secular volume growth has overwhelmed price erosion. (FACT — log cycle data.)

2. Competitive intensity vs. scale leaders. Vishay names its competitors directly in the 10-K, and the list is a who’s-who of larger, better-capitalized rivals: (FACT — 10-K “Competition”)

• MOSFETs: Infineon, Nexperia, ON Semiconductor, Renesas, STMicroelectronics, Toshiba.
• Diodes: Diodes Inc., Nexperia, ON Semiconductor, Rohm, STMicroelectronics.
• Optoelectronics: Broadcom, ON Semiconductor, Renesas, Toshiba.
• Resistors / Inductors / Capacitors: Bourns, KOA, Murata, TDK-EPCOS, Yageo, Panasonic, Taiyo Yuden, Kyocera, Nichicon, Rohm.

In power MOSFETs — the segment the AI narrative is built on — Vishay competes against Infineon and onsemi, both multiples of Vishay’s size with leading-edge fabs, full SiC/GaN roadmaps, and gross margins in the mid-40s to 60s vs. Vishay’s MOSFET segment GM of 9.8%. In passives, the global leaders are Murata, TDK, and Yageo, each with scale, captive MLCC fabs, and Japanese/Taiwanese cost positions Vishay cannot match. Vishay is #2–#4 in most lines and a clear leader in almost none (it claims worldwide leadership only in rectifiers and certain power-metal-strip resistors and wet-tantalum/MicroTan capacitors — genuine but small niches). The 10-K’s own framing is telling: it positions itself as the “independent second-source supplier” that benefits from consolidation among its larger rivals. (FACT — 10-K “Competition.”) Being the designated #2 alternate-source is a real role, but it is structurally a price-taker’s role, not a price-maker’s.

3. The capital cycle (Marathon lens). This industry is a textbook supply-side cautionary tale, and Vishay is positioned on the wrong side of it. The 2021–22 components shortage (post-COVID demand spike + supply chain chaos) drove the entire industry — Vishay, Infineon, onsemi, Murata, TDK, Yageo — to announce massive multi-year capacity expansions. That capacity is now landing into a glut: FY24/FY25 saw the inventory correction, falling utilization, and the collapse of Vishay’s margins to net losses. Per Marathon, capacity added at the top of the cycle depresses returns for years, and the data confirm it: industry-wide ASPs and utilization remain soft even as volumes recover. Vishay is simultaneously (a) still digesting the last glut and (b) spending into the next one — its “Vishay 3.0” plan is a 5-year, capex-heavy capacity build (2026 capex guide $400–440M, ~10–11% of revenue, half of it the Itzehoe 12-inch fab), explicitly producing negative free cash flow in FY24, FY25, and (guided) FY26. (FACT — log/transcript.) In Marathon terms, this is rising capex-to-depreciation, falling cash conversion, and asset growth into a soft market — the classic negative capital-cycle signature, not the consolidation/capacity-out signature that precedes a durable return inflection. The bull case requires the demand wave (electrification + AI power) to arrive before the industry’s collective capacity does — a demand-side bet, exactly the bet Marathon warns is the hardest to win.

End-market demand drivers. (FACT for content disclosure; INTERP for assessment.)

• Automotive (35.5%): electrification raises semiconductor + passive content per vehicle (an EV/HEV carries far more power MOSFETs, current-sense resistors, DC-link capacitors, and magnetics than an ICE car). This is the most credible secular content-growth driver, but it is overlaid on a cyclical and currently soft auto-production backdrop, and Vishay competes here against Infineon/onsemi/STMicro who dominate auto-grade power.
• Industrial (34.7%): factory automation, 5G, renewable/solar inverters — cyclical, currently in the late stages of a destocking correction.
• Military & Aerospace (10.2%): the bright spot — growing (FY23 $271.9M → FY25 $314.1M), higher-margin, longer design cycles, defense-budget-driven, less cyclical. Genuinely attractive but only ~10% of revenue.
• “Other”/AI data-center (~15%): the narrative driver. Management’s own disclosure is that AI exposure was <$100M (<5% of revenue) in FY25 — the AI story is a 2026+ hope, not a present reality. (FACT — log/transcript.)

Nexperia disruption — a real but transient tailwind. A late-2025 supply disruption at Nexperia (a direct competitor in auto MOSFETs and diodes) is letting Vishay win second-source share in automotive power semis. (FACT — Q1-26 transcript, log.) This is real incremental revenue and partly explains the Q1-26 book-to-bill of 1.47 in semis. But it is a competitor’s stumble, not a Vishay advantage — exactly the kind of one-time share gift the 10-K’s “independent second-source” positioning is built to capture, and exactly the kind of gain that reverses when the disrupted rival recovers. It flatters near-term orders; it does not change the structural economics.

Verdict (§7.2): structurally a BAD industry. This is a fragmented, commoditized, capital-intensive, price-taking business with secular ASP erosion, a glut still being digested, and Vishay’s larger rivals (Infineon, onsemi, Murata, TDK, Yageo) holding both scale and cost advantages. The redeeming features — electrification content growth and the defense niche — are real but partial, and they sit on top of a brutal supply side that Marathon analysis flags as negative: the whole industry, Vishay included, is building capacity into uncertain demand. The capital cycle here destroys returns more often than it rewards them, and Vishay is currently a net spender of capital into that cycle. A good industry lets a mediocre operator earn decent returns; this is a bad industry that punishes even good operators — and Vishay is, at best, an average one.

4. Competitive Position

The Greenwald question: is there a barrier to entry that lets Vishay do something its rivals cannot? Walk the three (and only three) genuine advantage types:

1. Economies of scale + customer captivity (the strongest moat) — ABSENT. Scale advantage is about share of the relevant market, not absolute size, and it only works combined with captivity. Vishay has neither dominant share nor captivity in its major lines. It is #2–#4 against Infineon/onsemi in power semis and against Murata/TDK/Yageo in passives — all of which are larger in the relevant markets and enjoy lower cost positions. The financial test is decisive: a scale-with-captivity moat shows up as sustained 15–25%+ ROIC; Vishay’s peak ROIC was ~17% (FY22, cycle top), falling to ~11% (FY23) and NEGATIVE (FY24/FY25). (FACT — ROIC.ai, log.) A business whose best year barely clears a high-teens ROIC and whose normal-to-trough years sit below the cost of capital does not have a scale moat. Greenwald’s market-share-stability test also fails: Vishay’s lines are exactly the kind of standardized, second-sourced parts where share moves with price and capacity, not loyalty.

2. Customer captivity / switching costs — WEAK and bounded. There is a real but narrow source of stickiness: in automotive and military/aerospace, parts must be “designed in” and qualified through long (12–24+ month) certification cycles, after which re-qualifying an alternate vendor is costly and slow. This creates genuine, multi-year stickiness on certified and custom parts (74% of revenue is certified+custom). (FACT — 10-K product mix.) But pressure-test it:

• The captivity attaches to the qualified part, not to Vishay — customers deliberately qualify multiple sources (Vishay’s own “independent second-source” pitch depends on customers refusing single-source captivity). Switching costs that you share with two or three rivals are not a moat; they are a shared barrier that caps everyone’s pricing power jointly, exactly the prisoner’s-dilemma structure Greenwald describes.
• It is strongest precisely where Vishay is smallest: defense is ~10% of revenue, automotive ~35% but second-sourced and contested by larger auto-power leaders.
• If this stickiness were a real moat, it would show in pricing power — and it does not: ASPs erode ~1–3%/yr even on these parts, and the segment that should be stickiest (MOSFETs, heavily auto/certified) is the one losing money.

3. Supply/cost or proprietary-technology advantage — ABSENT (and Greenwald’s weakest category anyway). Vishay has brands (Siliconix, Dale, Sprague, Vitramon, IHLP, BCcomponents) and patents, but in commodity components “in the long run everything is a toaster” — process know-how diffuses, patents expire, and the larger rivals out-spend Vishay on R&D ($122M, 4% of revenue) by an order of magnitude. There is no proprietary technology Infineon, onsemi, Murata, or TDK lack. The brands carry reputation (useful in qualification) but not pricing power — Greenwald’s Mercedes lesson: the best-known name in a market can still earn only average returns if there is no barrier behind the brand.

The genuine — but weak — edges, weighed honestly:

• Breadth / “one-stop shop”: Vishay can populate >80% of the components on many boards from a single catalog, and its FAE/solution-selling model leverages that breadth. (FACT — 10-K “Vishay Solutions.”) This is a real convenience advantage in distribution and engineering support — but it is a service feature, not a barrier; TI, Murata, and the big distributors (Avnet/TTI) offer comparable breadth, and breadth has not translated into superior margins.
• Independent second-source positioning: valuable when rivals consolidate or stumble (Nexperia today), but inherently a price-taker’s role.
• Brand legacy in niches: genuine leadership in rectifiers, power-metal-strip resistors, wet-tantalum capacitors, IHLP inductors — these are the segments earning 16–28% margins (Inductors, Resistors, Capacitors). This is the real Vishay moat, such as it is: scale-in-niche in a handful of specialty passive lines (Greenwald’s “small-market scale” — the only place scale advantages survive). But these niches are small and do not extend to the broader (and larger) commodity semiconductor portfolio.

Direct economic comparison vs. the leaders (the most damning evidence): (FACT — VSH 10-K; peer GMs are industry-standard ranges / per peer cross-reads.)

The gap is not subtle. Texas Instruments earns ~3x Vishay’s gross margin on its analog parts; onsemi and Infineon earn 2–2.5x on power semis. Even Advanced Energy — a mediocre cyclical the firm just covered — runs ~40% gross margin, double Vishay’s. Margin is the scoreboard of competitive advantage, and Vishay is at the bottom of its peer set. The reason is structural: TI/Infineon/onsemi have scale + leading-edge fabs + analog/power IP that confer real cost and differentiation advantages; Vishay has breadth and a second-source franchise that confer neither.

Verdict (§7.3): crowded commodity market with weak, narrow differentiation — NO durable competitive advantage in aggregate. Vishay flunks every Greenwald test: no dominant share, no captivity it doesn’t share with rivals, no proprietary technology, sub-15% through-cycle ROIC, and gross margins half to one-third of its scaled peers. The real edges — niche leadership in specialty passives (the cash-generating Resistors/Inductors/Capacitors lines) and the design-in stickiness of certified auto/defense parts — are genuine but bounded scale-in-niche advantages that protect maybe a third of the business and produce, at best, average returns. The semiconductor half is a contested, loss-making, capex-hungry commodity business with no moat at all. Net assessment: a no-moat business with a few defensible niches — a price-taker, not a price-maker. Whatever the stock is pricing, it is not a durable franchise.

5. Growth History and Forward Opportunities

6. Financial Quality

Revenue composition and the cyclicality problem

[F] Vishay’s revenue is deeply cyclical, swinging on the global electronic-components inventory cycle. Net revenues: FY18 $3,035M → FY20 trough $2,502M → FY22 peak $3,497M → FY24 trough $2,938M → FY25 $3,069M (FY25 10-K, Consol. Statements of Operations, filed 2026-02-13). The peak-to-trough revenue swing is only ~15%, but the earnings swing is violent because the cost base is heavily fixed (capital-intensive fabs, owned plants, defined-benefit pension overhead).

[F] The operating-leverage math is the whole story:

(FY25 10-K Statements of Operations; FY23 10-K for FY22.) [F] Revenue fell ~12% from FY23 to FY24 and gross margin collapsed 730 bps (28.6%→21.3%); operating income fell 99% ($486M→$5.6M). That is ~5–6x operating de-leverage on a ~12% revenue decline — the signature of a high-fixed-cost commodity manufacturer with no pricing power. [I] On the way back up the leverage works in reverse (Q1-26 gross margin already recovering to 21.0%, op margin 2.6%), but the point stands: VSH earns its money in the top third of the cycle and gives most of it back in the bottom third. This is a price-taker, not a moat business.

[F] FY24 GAAP operating income of $5.6M is artificially depressed by two one-time operating charges: $66.5M goodwill impairment + $40.6M restructuring/severance = $107M (FY25 10-K, Notes 3 and 19). Normalizing those back, FY24 “clean” operating income was ~$113M (op margin ~3.8%, matching the log’s 3.8% figure). FY25 had no goodwill impairment and no restructuring line — so FY25’s 1.85% margin is the genuinely “clean” trough. [I] Even normalized, both years are trough-level; the business is barely profitable at the operating line at this point in the cycle.

EBITDA vs. real free cash flow — the central quality-of-earnings flag

[F] This is the crux. Vishay generates positive operating cash flow but negative free cash flow because of the “Vishay 3.0” capex ramp. From the FY25 10-K’s own “Free cash” reconciliation (MD&A):

[F] So FCF was −$143.4M (FY24) and −$87.8M (FY25), and was barely positive (+$37.4M) even in FY23. [F] Management is explicit: “Despite generating negative free cash flow in 2025 primarily due to our [capacity] expenditure plans…” and “for 2026 we once again expect negative free cash flow” (FY25 10-K MD&A; Q1-26 transcript). [F] 2026 capex guidance is $400–440M (~13–14% of revenue), approximately half on a 12-inch (300mm) wafer fab in Itzehoe, Germany (FY25 10-K MD&A; Q1-26 10-Q MD&A).

[F] Q1-26 confirms the bleed: capex $110.7M (vs $61.6M Q1-25 — nearly doubled); reported OCF $63.7M; FCF ≈ −$47M (log). [I] D&A was $224.7M in FY25 (depreciation alone $211.5M) versus capex $273M — VSH is spending ~1.3x its depreciation, and guiding to ~2x depreciation in 2026. This is a multi-year capital build into a cyclical trough.

[F] QoE FLAG #1 — accounts-receivable securitization is flattering operating cash flow. In Q4-2025 VSH began selling non-U.S. receivables on a non-recourse basis. It had $62.2M outstanding at Dec-31-2025, growing to $125.3M at Apr-4-2026 (FY25 10-K Note 1; Q1-26 10-Q Note). The cash proceeds are booked as operating cash flow. [I] The +$63M increase in the program during Q1-26 is essentially the entirety of the $63.7M of OCF Vishay reported that quarter — strip it out and Q1-26 operating cash flow was roughly break-even (~$0.6M). The facility is sized up to ~$150M (Q1-26 10-Q), so this lever is nearly maxed — it can be used once, not repeatedly. Reported OCF should be read net of this financing-in-disguise.

Returns on capital — use ROIC, not ROE

[F] ROE is distorted and not useful here: book equity is $2,088M but tangible book is depressed by $180M goodwill + $259M intangibles, and the FY24/25 net losses make ROE negative/meaningless. [F] ROIC (ROIC.ai series): FY22 peak ~17.1% → FY23 11.1% → FY24/FY25 negative. [I] Even the peak ROIC of ~17% is only modestly above a ~9–10% WACC, and the business spends years below WACC at the bottom. Across a full cycle VSH is, at best, a marginal value-creator and frequently a value-destroyer on invested capital. This is consistent with a commodity/scale-in-niche components maker (Greenwald: cost/scale advantage in a few niches, no broad moat).

Balance sheet, leverage, liquidity runway

[F] Capital structure at Dec-31-2025 / Apr-4-2026:

• Cash & equivalents: $515.0M (Dec-25) → $479.4M (Apr-26); plus modest short-term investments. Down from ~$1.0B in FY23.
• 2.25% Convertible Senior Notes due 2030: $750.0M principal, issued Sep-2023, coupon 2.25%, effective conversion price $30.16/sh (33.1609 sh per $1,000), cap-call cap price $43.98. Maturity Sep-15-2030; not redeemable before Sep-2027; principal cash-settled, excess in cash/shares. (FY25 10-K Note 6.)
• Revolving credit facility ($750M, JPMorgan-led, matures May-2028): $219M drawn at Dec-25 → $250M at Apr-26; ~$307M usable capacity remaining. Secured by substantially all U.S. assets + foreign stock pledges. (Q1-26 10-Q.)
• Long-term debt (total): $950.9M (Dec-25), incl. converts + revolver + finance leases.
• Long-term lease liabilities: $95.8M (total operating-lease liability ~$119.7M).
• Pension & OPEB net liability: $172.7M (U.S. plans −$27.6M; non-U.S. −$126.1M; OPEB/other −$19.0M). (FY25 10-K Note 11.)
• Repatriation / transition-tax liabilities: ~$81M accrued repatriation tax on ~$561M of non-indefinitely-reinvested foreign earnings (Q1-26 10-Q). Much of the cash is trapped offshore (Germany, Israel) — VSH is in a net borrowing position in the U.S. and expects to stay there through 2026.

[F] Leverage covenants (Q1-26 10-Q): net leverage 2.34x (covenant max 3.25x); interest coverage 9.70x (min 3.25x) — currently compliant with headroom. But the pricing-basis total leverage ratio is 3.07x, and the credit facility restricts dividends/buybacks once pro-forma net leverage exceeds 2.50x and restricts acquisitions above 2.75x. [I] VSH is bumping up against the levels at which its own credit agreement throttles capital return and M&A. The 2030 converts have cross-default provisions tied to the revolver.

[F] Liquidity runway: ~$479M cash + ~$307M revolver availability ≈ ~$786M of liquidity against a planned ~$400–440M of 2026 capex, ~$54M dividends, and trapped offshore cash. [I] The runway is adequate for 2026 but not generous — the company is funding the growth plan by drawing down cash, drawing the revolver, securitizing receivables, and (in 2023) issuing the $750M convert. If the recovery stalls, the next funding lever is more debt or equity, not internal cash.

Inventory and working capital

[F] Inventory is rising into the recovery: $759M at FY25 (log), with obsolescence write-offs of $35.0M (FY25), $37.2M (FY24), $37.4M (FY23) — i.e. ~$35–37M of inventory is written off every year as a recurring cost of a commodity business with thousands of SKUs (FY25 10-K cash-flow statement). [I] These write-offs are routine, not one-time; they are a structural drag, not a clean-up. The inventory build supports the demand recovery (book-to-bill 1.34, backlog +21%), but ties up cash during the burn.

Stock-based compensation, dilution, share count

[F] SBC is low: $22.4M (FY25), $20.9M (FY24), $16.5M (FY23) — under 1% of revenue and ~0.7% of market cap. [I] Unlike the SaaS names, SBC is not a quality-of-earnings problem at Vishay; the FCF deficit is real cash capex, not stock-comp masking. [F] Shares issued fell to 123.5M (Dec-25) from 133.6M (Dec-24) after VSH retired 10.66M treasury shares ($224.6M) in Q4-25 — but this was a retirement of previously-bought treasury stock, not new buyback activity. Diluted share count is ~136M; the 2030 converts (deep in-the-money at $56 vs $30.16 strike) reserve 24.87M shares, and Class B conversion reserves another 12.10M (FY25 10-K Note 7).

Tax rate — messy, volatile, and value-relevant

[F] The effective tax rate is not meaningful at current low pre-tax levels and produces perverse results:

• FY25: pre-tax income $25.5M, tax expense $34.5M → net loss of $9.0M (effective rate ~135%).
• FY24: pre-tax loss of $2.4M, tax expense $27.4M → net loss $29.8M.
• FY23: pre-tax $467.4M, tax $141.9M → ~30.4% rate.

[F] Management states the GAAP rates for FY24/25 “are not meaningful at the low levels of pre-tax loss” and that “when pre-tax earnings increase, we expect that our effective tax rate will be higher than the U.S. statutory rate” (FY25 10-K MD&A). [F] Drivers: jurisdictional income mix (high-tax Germany/Israel vs. U.S.), a $9.4M valuation allowance on a foreign-tax-credit DTA, GILTI/“net CFC tested income” changes expected to raise future rates, and accrued repatriation/transition-tax liabilities being paid down (~$47M U.S. transition-tax payment in FY25). [I] The structurally high (>statutory) and volatile tax rate is a permanent headwind to normalized EPS — even in good years VSH keeps less of pre-tax income than a U.S.-statutory model would suggest. Any bull EPS estimate must use a high-20s-to-30%+ tax rate, not 21%.

QoE flags summary

1. A/R securitization flattering OCF (+$63M of Q1-26 OCF; $125M outstanding) — financing dressed as operations. [F]
2. Capex-driven negative FCF — EBITDA/op-income overstate cash generation; real FCF has been negative two straight years and guided negative again. [F]
3. FY24 one-time charges — $66.5M goodwill impairment + $40.6M restructuring depress reported FY24, but normalizing still leaves a trough. [F]
4. Recurring inventory obsolescence (~$35–37M/yr) — a structural cost, not a clean-up. [F]
5. Tax-rate distortion — net losses on positive pre-tax income; high structural rate. [F]
6. Comp add-back — FY25 adjusted EBITDA of $264.2M (8.6% margin) excludes an $11.3M “favorable resolution of contingency”; modest but watch the adjustment creep. [F]

VERDICT (7.5): Do economics improve with scale? — No, not durably.

[I] Vishay’s economics are dominated by cyclicality and capital intensity, not scale-driven margin expansion. Gross margin peaks ~30% and troughs ~19–21%; ROIC peaks ~17% and goes negative at the bottom. The current capex super-cycle is a bet that future scale (the German 12-inch fab, AI/EV content) lifts structural margins toward the 2024 Analyst-Day target (31% GM / 20% op margin) — but that target has been “delayed,” current adjusted EBITDA margin (8.6%) missed its own 11.3% comp target, and the cash cost of the bet is two-plus years of negative free cash flow. The economics are mediocre-cyclical with an unproven, expensive growth option attached. The QoE picture is “trough earnings, negative free cash, OCF propped by receivables sales” — read EBITDA with heavy skepticism.

7. Capital Allocation

The “Vishay 3.0” capex thesis — the dominant capital-allocation decision

[F] The defining capital-allocation choice is the multi-year capacity build. Capex: $329M (FY23), $320M (FY24), $273M (FY25), guided $400–440M for 2026 (~13–14% of sales). [F] Cumulative 2023–2026E capex ≈ $1.3–1.4B, against cumulative operating cash flow over the same window of only ~$0.8B — i.e. the program is deficit-funded. ~Half of 2026 capex is the Itzehoe, Germany 12-inch wafer fab; the rest expands resistor, inductor, MOSFET, and diode capacity. The 2024 Analyst-Day frame: grow revenue to ~$5.5B by 2028 (10% CAGR), 31% GM, 20% op margin, $5+ EPS — all explicitly “delayed.”

[I] Apply Marathon / Capital Returns (capital-cycle lens): Vishay is adding capacity into a components downcycle, at the same time as the broader power/components industry (onsemi, Infineon, STMicro, TI, Bosch) is also expanding for EV/AI. This is the textbook supply-side warning sign — high-return narratives (AI, electrification) attracting heavy capital across an entire industry, which historically compresses returns when the capacity lands. VSH is a price-taker spending to chase volume share, not a differentiated leader earning excess returns. The risk is that the German fab and expanded lines come online into a glut, pressuring the very margins the spend was meant to lift. [OQ] Will the AI/EV demand (mgmt: AI was <$100M / <5% of FY25 sales, “well above that” in FY26) actually absorb the new capacity at accretive margins, or is this share-chasing into a commoditizing end-market? The financial evidence (negative FCF, ROIC below WACC, missed margin targets) currently argues for skepticism.

[F] One mitigant: VSH says ~82% of 2025 capex went to “capacity expansion projects for high-growth product lines” and it can flex spend via outsourcing commodity products to subcontractors (FY25 10-K MD&A) — so the program has some optionality and is not 100% sunk.

M&A history

[F] Vishay is a serial acquirer (built since 1985 by Felix Zandman via roll-up — Dale, Sprague, Vitramon, Siliconix, BCcomponents, etc.). Recent M&A is modest: FY24 “Purchase of businesses, net of cash acquired” = $216.0M, of which the largest piece was the Newport Wafer Fab (Newport, South Wales, UK), acquired in 2024 from Nexperia for ~$177M (log; FY24 8-K timeline). [F] Per the Q1-26 transcript, Newport only recently reached gross-profit-neutral — i.e. it has been a drag on margins during ramp. [I] The Newport acquisition is strategically logical (captive 200mm wafer capacity, supply-chain control, supports the MOSFET/diode share gains vs. a supply-disrupted Nexperia) but it is a fixer-upper that consumed cash and gross margin for two years before contributing. The credit facility now restricts further acquisitions while pro-forma net leverage exceeds 2.75x — so the M&A engine is currently throttled by the balance sheet.

Dividend — funded by borrowing during the burn

[F] Vishay pays ~$0.10/qtr (~$0.40/yr); total dividends $54.2M (FY25), $54.7M (FY24), $55.6M (FY23) — split common $49.4M + Class B $4.8M (FY25). [F] The 2022-adopted Stockholder Return Policy calls for returning “at least 70% of free cash flow, net of scheduled principal payments,” via dividends and buybacks. [I] This policy is currently moot/inverted: free cash flow is negative, so 70% of FCF is a negative number — yet the dividend is still being paid. The ~$54M/yr dividend is therefore being funded out of cash drawdown and revolver borrowing, not free cash. Management is in effect borrowing to pay the dividend during the growth-capex phase. The dividend is not at imminent risk (it’s small relative to liquidity and the credit facility permits dividends up to $100M/yr even above 2.50x leverage), but it is not covered by FCF and won’t be until the capex cycle ends and the recovery delivers.

Buybacks — appropriately absent at these prices

[F] Stock repurchases: $78.7M (FY23), $50.4M (FY24), $12.5M (FY25), $0 in Q1-26 (cash-flow statements). [I] To management’s modest credit, buybacks were throttled to near-zero as the stock tripled (from ~$14–18 in spring-2025 to ~$56) — they are not buying back richly-valued stock. But the flip side: there were no large opportunistic buybacks at the bottom either ($14–16 in mid-2025), because the balance sheet was committed to capex and the dividend. The Q4-25 retirement of 10.66M treasury shares ($224.6M) was an accounting tidy-up of stock bought in prior years, not fresh return.

Convertible-dilution risk

[F] The 2030 converts ($750M, strike $30.16) are deeply in-the-money at the current ~$56 price. The principal is cash-settled (VSH intends to fund it via revolver borrowing), but value above principal can be settled in shares; the capped call (cap $43.98) offsets dilution only up to $43.98 — above $43.98 the capped call is exhausted and incremental conversion value dilutes shareholders. 24.87M shares are reserved. [I] At $56, real economic dilution risk exists on conversion/maturity, and refinancing the $750M principal in 2030 (or earlier conversion) will require fresh borrowing — adding to a balance sheet already at ~3x pricing leverage. This is a latent claim on future cash/equity that the bull case under-weights.

Insider behavior — a genuine, broad-based buy cluster at the bottom

[F] SEC Form 4 read (full 153-filing corpus, 2024–2026; codes: 58 A-grants, 50 F-tax-withholding, 10 P-purchases, 7 S-sales, 1 D):

Open-market PURCHASES (code P) — a cluster in May–June 2025 near the cycle low:

[F] This is the single most bullish data point in the capital-allocation read. Across ~one week in May-2025 the CEO, CFO, COO, and several EVPs/directors all bought on the open market at ~$14.40–16.12 — within ~10% of the cycle low. These are discretionary, code-P purchases (rare and high-signal), not 10b5-1 sales or grants. [I] At ~$56 today those purchases are up ~3.5–4x; management put real personal cash to work at the bottom and was right.

[F] Sales (code S) are concentrated in the Zandman family/older directors trimming on the way down (not executives): Marc Zandman sold ~88K shares across Jan-2024–Mar-2025 at $16.71–22.83; directors Ludomirski (75K @ $23.84, Dec-2023), Zilberman (16K @ $23.58, Jun-2024), and Cody (8.7K @ $18.28, Dec-2024) trimmed. [I] The Zandman sales are family diversification/estate-type activity at higher prices, not a conviction signal; the more telling fact is that operating management bought at the bottom and is not selling into the rally. [F] The 50 “F” codes are routine share-withholding on RSU vesting; the 58 “A” codes are routine grants. No 10b5-1 executive selling program is evident.

Compensation & incentive alignment — the family-control red flags

[F] Dual-class, family-controlled. Class B common stock carries 10 votes/share (common = 1 vote). Ruta Zandman (founder Felix Zandman’s widow) holds sole/shared voting power over ~44.3% of total voting power (2026 DEF 14A); her son Marc Zandman is Executive Chairman, Chief Business Development Officer, and Chair of the Equity Award Committee. 12.10M Class B shares are convertible 1:1 to common. [I] The family effectively controls the company despite a minority economic stake — public shareholders have limited governance leverage. Say-on-pay “passed” with >98% support (2026 proxy), but with ~44% of the vote family-controlled, that vote is not a meaningful market check.

[F] NO ROIC OR ROE METRIC in executive compensation. The 2025 incentive metrics are: adjusted EBITDA margin (30% weight) + adjusted gross profit margin (20%) + Transformation/Individual Scorecards; the long-term equity uses relative TSR (rTSR) vs. the Philadelphia Semiconductor Index; “Adjusted Net Earnings” is cited as the most important pay-vs-performance measure. [I] This is a material red flag for a capital-intensive, value-on-invested-capital business: management is paid on margins and growth, not on returns on the capital it is deploying. A $1.3B+ capex program that lifts EBITDA margin while ROIC stays below WACC would still pay out — the comp scheme actively rewards the “spend for scale” strategy regardless of whether it creates value per dollar invested. The absence of any capital-efficiency hurdle is precisely the wrong incentive given the Vishay 3.0 bet.

[F] To the comp scheme’s credit, the FY25 adjusted-EBITDA-margin metric (8.6% actual vs. 11.3% target) paid out 0% — so the formula did discipline cash bonuses in the trough year. [F] CEO Smejkal’s FY25 total comp was $10.34M (mostly $8.25M stock awards; $1.03M salary; $1.03M non-equity incentive). [F] Watch item: Executive Chairman Marc Zandman received a $500K discretionary “bonus” in FY25 (a loss year) plus an $845K pension-value increase, total comp $4.91M — a discretionary family payout in a year the formula paid executives 0% on the EBITDA metric. [F] Mrs. Ruta Zandman (director, not an operating executive) received $150K in addition to her $70K retainer “for her role in preserving the memory of the late Dr. Felix Zandman and the Company’s corporate history.” [I] These are minor in dollar terms but emblematic of a founder-family-run company where governance and pay norms bend to the family.

VERDICT (7.6): Has management allocated capital intelligently? — Mixed, leaning cautious; the jury is out and the incentives are misaligned.

[I] The scorecard is genuinely split. Positives: (1) management bought stock heavily at the bottom with personal cash and was vindicated; (2) buybacks were correctly throttled to ~zero as the stock tripled — no value destruction buying high; (3) the $750M convert at 2.25%/$30.16 strike and the capped call were shrewdly-priced 2023 financing; (4) the comp formula did pay 0% on the missed FY25 margin metric. Negatives / open risks: (1) the entire thesis hinges on a $1.3B+ deficit-funded capex program into a cyclical trough and an industry-wide capacity build — Marathon’s capital-cycle framework flags this as the kind of high-conviction spend that historically disappoints, and current ROIC sits below WACC; (2) the dividend is being funded by borrowing because FCF is negative and the “70% of FCF” policy is moot; (3) Newport was a cash-and-margin-consuming fixer-upper for two years; (4) no ROIC/ROE in the comp scheme — management is paid to grow margins and revenue, not to earn a return on the capital it deploys, which is exactly the wrong incentive for this strategy; (5) family super-voting control (~44% via 10-vote Class B) removes the market’s governance check. Net: capital allocation is defensible and disciplined at the margin (insider buys, no high buybacks) but strategically high-risk at the core (the capex bet), with incentives that fail to hold management accountable for capital efficiency.* Whether it was “intelligent” will be known only when the German fab ramps and the cycle turns — today the financial evidence (negative FCF, sub-WACC ROIC, missed margin targets) does not yet validate the bet.

8. Changes and Headwinds — Last Two Years

The last two years reframed Vishay from a sleepy cyclical into a high-capex transformation story, and the changes are a mix of genuine strategic shifts, a deepening trough, and a few governance/financing events that bear on the thesis.

Strategic / operational.

• “Vishay 3.0” capital build (2023–present). The defining change is the launch and execution of CEO Joel Smejkal’s 5-year, eight-lever growth plan, anchored by a multi-year capacity expansion: the Newport Wafer Fab (South Wales, UK) acquired from Nexperia in 2024 for ~$177M (200mm capacity for MOSFETs/diodes; only reached gross-profit-neutral by Q1-26 after two years as a margin drag), and the 12-inch (300mm) wafer fab in Itzehoe, Germany (~half of 2026’s $400–440M capex; non-automotive production targeted mid-2027). (FACT — 10-K, Q1-26 transcript.) This is a deliberate pivot from a capital-light “Vishay 2.0” allocation model to a capacity-led “scale-with-the-customer” model — strengthening the long-term franchise option but, in the near term, the source of three straight years of negative free cash flow.
• Restructuring (Sept-2024). A footprint-optimization program (three site closures) took a $40.6M FY24 charge, targeting ~$23M of annualized savings by end-2026. A further restructuring is flagged on the Q1-26 call as the next lever to support gross margin after the capex peak. (FACT.)
• Management transition. David McConnell appointed EVP-CFO effective 2026-03-01 (the CFO who is now executing the balance-sheet stretch). CEO Smejkal (since 2023) and Executive Chairman Marc Zandman remain in place. (FACT — 8-K timeline.)

Demand / cycle.

• The deepest trough in a decade, then a real inflection. FY24 produced a GAAP loss and FY25 an operating margin of 1.85%; the stock bottomed at $10.28 in April-2025. The inflection since is genuine: book-to-bill rose to 1.34 (semis 1.47, passives 1.23), backlog +21% to $1.6B (5.7 months), Q1-26 revenue +17% YoY, with Q2-26 guided to $875–905M and gross margin ~22%. (FACT.) Whether this is an early-innings multi-year up-cycle (bull) or a normal mid-cycle bounce (bear) is the central open question.
• Nexperia disruption (late-2025). A supply disruption at competitor Nexperia is handing Vishay incremental second-source automotive MOSFET/diode share — a real near-term order tailwind, but a competitor’s stumble rather than a durable Vishay advantage. (FACT/INTERP.)
• AI/electrification narrative. Management began quantifying AI exposure (<$100M, <5% of FY25 revenue; guided “well above that” in FY26) and emphasizing 800V data-center power content — the reframing that, more than any margin print, drove the re-rate. (FACT.)

Financial / capital structure.

• Balance-sheet stretch. Cash fell from ~$1.0B (FY23) to $480M (Q1-26); the company drew its U.S. revolver to $250M, began an A/R securitization program ($62M → $125M), and the $750M 2.25% converts (issued 2023, $30.16 strike) are now deep in-the-money. Net leverage is 2.34x (covenant max 3.25x) — compliant but approaching the 2.50x level at which the credit agreement throttles capital return. (FACT.)
• One-time items distorting the run-rate. FY24 carried a $66.5M goodwill impairment; FY23 a –$18.9M debt-extinguishment loss; recurring ~$35M/yr inventory obsolescence; and a volatile, >100% effective tax rate at trough pre-tax levels. (FACT.)

Macro / regulatory. Tariff policy whipsawed demand timing (Asia pull-forwards ahead of U.S. tariffs in 2H-25; a 2026 Supreme Court ruling striking certain IEEPA tariffs noted as a Q1-26 subsequent event). (FACT.)

Verdict (§7.7): the changes strengthen the long-term franchise option but weaken the near-term financial profile — and the price response has run far ahead of either. The capacity build, defense ramp, and electrification content are real positives for the 2027+ earnings power; the negative free cash flow, balance-sheet stretch, dividend-funded-by-borrowing, and convert dilution are real near-term negatives. On net the operational news is incrementally constructive, but nothing in the last two years justifies a tripling of the stock to a richest-ever multiple — that is a sentiment event layered on a modest fundamental inflection.

9. Risk Analysis (Risk Matrix)

The dominant risk is valuation/mean-reversion, not solvency: a high-beta, no-moat cyclical at a richest-ever multiple on trough earnings is structurally fragile to any narrative crack. The second tier is execution/capital-cycle risk (the deficit-funded capacity bet landing into a glut). Solvency risk is real but lower (compliant covenants, no maturities until 2028).

Net read: the risk matrix is unusually valuation-loaded. There is no plausible catastrophic-loss scenario, but there is a wide, high-probability band of outcomes — anything short of full bull-case execution — in which the stock mean-reverts hard from a richest-ever multiple. The asymmetry (large mean-reversion downside vs. modest incremental upside if the bull case is already largely priced) is what drives the AVOID-here framing in Claude’s Take.

10. Valuation Discussion (Embedded Expectations)

2.1 The own-history fact pattern — richest-ever on every metric, on trough earnings

VSH is a low-return, capital-intensive, commodity-leaning maker of discrete semiconductors and passive components. Over a full decade its valuation has sat in a tight, low band. At $56.35 every multiple is at or near an all-time high, and the earnings denominator is at a cyclical trough (FY25 op margin 1.85%, near-zero GAAP EPS).

Live-price figures (FACT, derived; ~135.6M dil. sh × $56.35; total debt $1,101.7M − cash $479.4M = net debt $622.4M):

• Market cap ≈ $7.64B; net debt ≈ $0.62B; EV ≈ $8.26B.
• EV/EBITDA (TTM EBITDA $307M) ≈ 26.9x.
• EV/Sales (TTM $3.19B) ≈ 2.59x.
• EV/EBIT (TTM EBIT $78M) ≈ 106x.
• P/S ≈ 2.39x; P/B ≈ 3.66x; P/TBV ≈ 4.6x.

Own-history band (FACT, ROIC.ai 10-yr annual valuation series, year-end multiples):

P/B is distorted by negative/near-zero book years (FY16–18 had negative reported book equity); P/TBV is the cleaner book read and is also at a record. The composite AZI valuation_index is 99.3rd percentile of the stock’s own ~10-year range. (FACT.) Ignore the AZI/ROIC P/E percentile entirely — TTM GAAP EPS ≈ $0.016 makes the P/E ~99th-percentile reading a denominator artifact, not a signal (P/B, P/S, P/TBV are the valid own-history tells here.)

The single cleanest statement of the dislocation (INTERPRETATION): EV/EBITDA has never exceeded ~11.8x in a decade, yet sits at ~27x today. The market is paying ~10.6x VSH’s all-time-PEAK FY22 EBITDA ($779M) for a business currently generating $307M of TTM EBITDA and negative free cash flow. To make the current EV look “cheap” at a normal 8x, the company would have to already be earning more than its record-cycle peak.

2.2 Cross-sectional comp — most expensive name on the worst fundamentals

Discrete/analog and passives peers (TTM EV/EBITDA, ROIC.ai, at their own live prices):

INTERPRETATION: VSH trades at a higher EV/EBITDA than every higher-quality peer except MCHP (whose EBITDA is itself trough-depressed), while carrying the lowest EBITDA margin in the group (9.6%), the weakest returns (peak ROIC only ~17%, currently negative), and negative free cash flow. On EV/sales it screens “only” mid-pack (2.59x) precisely because its margins are so low — but normalize for quality and the EV/EBITDA gap is the honest read: the worst business in the cohort is priced like one of the best. For cohort context, the AEIS/VICR/SIMO reports on disk show the same 2026 pattern — mediocre cyclical semis-adjacent names re-rated to richest-ever multiples on the AI build-out narrative; VSH is the most extreme version (AEIS ~39x non-GAAP / 96th pctile; VICR richest-ever; VSH ~27x EV/EBITDA = ~10x peak EBITDA).

2.3 Embedded-expectations analysis — what must be true at $56.35

The question is not “what is VSH worth” (no price target) but what the $8.26B EV requires the business to deliver. Anchor to a normal exit EV/EBITDA of 8x (the midpoint of the stock’s own 3.6–11.8x decade band):

• To justify today’s EV at 8x EBITDA, VSH must reach ~$1.03B of EBITDA — i.e., ~1.3x its all-time-record FY22 EBITDA ($779M) and ~3.4x current TTM ($307M).
• That is essentially the 2028 Analyst Day vision in full: revenue ~$5.5B (vs. $3.07B FY25), gross margin ~31% (vs. 19.4%), operating margin ~20% (vs. 1.85%), ~$5 EPS. At ~$5.5B × ~20% op margin + D&A you arrive near $1.0–1.1B EBITDA. The current price embeds the company hitting the entire delayed Vishay 3.0 transformation AND a cyclical peak at the same time (ASSUMPTION/INTERPRETATION).
• Put differently: at $56.35 the market is underwriting VSH to simultaneously execute a structural margin transformation it has so far missed, and ride the cycle to a new peak — and is paying a premium multiple on top of that, not a discount. There is essentially no margin of safety for the cyclical or execution risk that has historically defined this name.

2.4 Scenario analysis (bear / base / bull) — FY28 normalized, illustrative

ASSUMPTIONS labeled; figures illustrative, NOT a forecast or target. EPS uses ~136M shares.

INTERPRETATION: the asymmetry is unfavorable. Even the base case leaves the stock above its own historical valuation ceiling, and only the full, on-time achievement of the aspirational (and explicitly “delayed”) 2028 plan brings the current price down to an ordinary 8x. The bear case — a perfectly normal outcome for a price-taking components maker — implies the stock is still being valued at ~24x trough/normal EBITDA, i.e., ~2–3x its historical multiple, leaving substantial downside to mean-reversion.

What the market is pricing correctly (INTERPRETATION): the cyclical trough has passed (book-to-bill 1.34, backlog +21%, Q1-26 rev +17% YoY); there is a real, if early, AI/electrification demand vector and genuine Nexperia auto-MOSFET share gains. What it is pricing incorrectly (INTERPRETATION): that this no-moat, ~10% capital-intensity, historically <17%-ROIC business deserves a peak-of-peak multiple on trough earnings; that the delayed Vishay 3.0 margin step-up is a near-certainty rather than an aspiration; and that 2026 — a year management itself guides to negative free cash flow with $400–440M capex — warrants the richest valuation in the company’s history.

11. Variant Perception

Consensus belief (what the $56 buyer is underwriting). VSH is an under-appreciated picks-and-shovels beneficiary of the AI-datacenter + electrification/EV super-cycle, where a cyclical bottom (book-to-bill 1.34, backlog +21%, Q1-26 rev +17% YoY) coincides with a once-in-a-generation demand vector — and, on top of that, the “Vishay 3.0” capacity-and-margin transformation (12-inch Itzehoe fab, Newport, Nexperia auto-MOSFET share gains) drives the company toward its 2028 targets (rev ~$5.5B, GM 31%, op margin 20%, ~$5 EPS). In that frame, today’s ~27x trough EBITDA is “cheap” against the future earnings power.

Strongest bull case. The trough is real and behind us; AI/electrification content per box is structurally rising; Nexperia’s late-2025 supply disruption is handing VSH durable auto share; Vishay 3.0’s owned 12-inch capacity converts a commodity maker into a higher-margin, more vertically-integrated supplier; if even half the 2028 margin plan lands at mid-cycle volume, EBITDA roughly triples to ~$1B and today’s price is ~8x — a normal multiple, with optionality above.

Strongest bear case. VSH is a no-moat, price-taking, capital-intensive components maker (peak-ever ROIC ~17%, currently negative; ~10–11% capex/sales; management guides 2026 to negative free cash flow). The market is paying ~27x trough EBITDA = ~10.6x all-time-PEAK EBITDA and the richest valuation in the company’s decade-long history (composite 99th percentile, EV/EBITDA >2x its prior all-time high) — on a cyclical, narrative-driven melt-up that has just begun to roll over (−13% to −19% off the high, alpha negative). The 2028 plan is aspirational and already “delayed”; the AI revenue is <5% of sales today. If the cycle merely normalizes (bear/base scenarios), the stock is worth a fraction of $56 on any historical multiple. Lifetime Sharpe 0.19 and −88% drawdown history warn how these episodes end.

The 3–5 assumptions that matter most, and what falsifies each:

Factor-positioning read folded in (INTERPRETATION). The tape says consensus is maximally offsides on the bullish side: a high-beta (β~2), small-size, anti-low-vol name that has tripled in a quarter on multiple expansion, with idiosyncratic vol ~39% and alpha just turned negative. Crowded-momentum positioning that has begun to fade is precisely where a narrative-driven re-rate is most fragile — the variant view is that the market has priced a best-case execution AND a cyclical peak simultaneously, into a business with no durable moat and a −88% drawdown pedigree, and the burden of proof has shifted entirely onto a delayed 2028 plan.

11.1 Price Action, Momentum & Factor Positioning (the tape, as evidence)

Factor loadings (FACT, FactorsToday “Base + Sector” model, 756-day window, R²=0.54; read within one model). VSH is, in factor terms, a high-beta, anti-low-vol, small-size, cyclical-tech stock:

• Market beta +1.58 (Base model +1.66; AZI/CSV realized beta ~2.00) — moves ~2x the market. (Base+Sector+Industry adds Industry: Semiconductors +0.74 and Sector: Technology +0.60.)
• LowVolatility −0.80 (strongly negative — a high-volatility name; deepens to −0.89/−0.97 in richer models) and SmallSize +0.77 — the classic profile of a small, jumpy, cyclical stock.
• DividendYield +0.50 (legacy of the ~$54M dividend) and Quality +0.26 (modest).
• No Value or Momentum style factor loads materially in this model — notable: the explosive 2026 move shows up as Market/Size/idiosyncratic, i.e., a stock-specific melt-up, not a clean style-momentum trade. The “All Factors” model attaches it to a “Semiconductor Powerhouse Stocks” custom basket (+0.66) — confirming it now trades as an AI/semis-theme vehicle.

Idiosyncratic risk (FACT): specific volatility ~39% annualized, with the model R² only ~0.66 — most of VSH’s risk is stock-specific, consistent with a narrative-driven single-name move rather than a sector beta trade.

Risk-adjusted track record (FACT, FactorsToday leaderboard, de-annualized where noted):

• Lifetime (≈20yr): Sharpe 0.19, Sortino 0.27, return +9.9%/yr, vol 42.6%, max drawdown −87.8%. Over a full multi-cycle history VSH has been a serial wealth-destroyer on a risk-adjusted basis — a punishingly volatile name that has lost ~88% peak-to-trough at least once and compounded poorly.
• 5-yr Sharpe 0.54 / 3-yr 0.61 — mediocre even before this year.
• 1-yr return +293% (raw); m3 +138% and m6 +1,528% are ANNUALIZED — de-annualized, the last 3 months ≈ +243% and the last 6 months ≈ +303%, i.e., the quarter roughly tripled the stock (consistent with the $17.97 → $64.90 = 3.6x price move). Short-window Sharpe (m3 ~175 ann.) is a parabola artifact, not a durable signal.
• alpha turning negative (−0.09 on 2026-06-26) as the stock fades ~13–19% off the high — the first quantitative sign the one-way move has stalled.

Regime / framing (INTERPRETATION). This is unambiguously a crowded, high-beta momentum trade — NOT a falling knife. The instinct to call cheap-looking semis names “falling knives” is wrong here: VSH is up ~290% in twelve months and ~5.5x off its low, trading ~2x above its 200-day EMA on an AI/electrification + Vishay-3.0 margin-transformation narrative, with ETF/momentum flows visible in the news tape (“300% breakout,” “respect the 21-day line”). The risk is not catching a knife; it is standing in front of a parabola that has begun to roll over — alpha negative, price −13% off the close high, momentum cooling. A high-beta name that has tripled on multiple expansion, with a lifetime Sharpe of 0.19 and −88% max-drawdown history, is the textbook setup for a violent mean-reversion if the narrative cracks. Hand to Claude’s Take: momentum/crowded-long that has just stalled, on a business whose own decade of valuation and risk-adjusted returns argues the move is sentiment, not earnings.

Factor-similar peers (FactorsToday related-stocks): the model clusters VSH with high-beta semis/components and AI-themed names — useful cross-check that the comp set (ON, DIOD, LFUS, plus the broader AI-semis cohort AEIS/VICR/SIMO on disk) is the right one, and that VSH is the cyclically-lowest-quality member trading at the richest EBITDA multiple.

12. Fact vs. Interpretation

13. Open Questions

1. Is the recovery early-cycle or mid-cycle? Book-to-bill 1.34 and backlog of 5.7 months are constructive, but distribution inventory (20 weeks) and the pace of true end-consumption (vs. replenishment) will tell whether this is a multi-year up-cycle or a bounce that fades in 2027.
2. Will Vishay 3.0 actually lift structural gross margin, or just cyclical margin? Q2-26 guide is ~22%; the bull case needs a durable climb toward the high-20s/31% target. Decomposing the next four quarters into volume/utilization (cyclical) vs. mix/ownership (structural) is the key tell.
3. When does free cash flow inflect positive? Management guides negative FCF for 2026; the German fab’s capex peak is mid-2026. Does 2027 deliver the first clean positive-FCF year, and at what level?
4. How material does AI revenue actually become? From <$100M today to what share of a (hoped-for) $5.5B by 2028? And is Vishay winning sockets or just second-sourcing them?
5. How durable are the Nexperia share gains once that competitor’s supply normalizes?
6. What is the all-in convert/refinancing path? With the 2030 converts deep ITM and the capped call exhausted above $43.98, how much dilution or fresh borrowing does the eventual settlement entail?
7. Does the family-controlled board ever adopt a capital-efficiency (ROIC) hurdle in comp — the missing governor on a capacity-led strategy?

14. What Must Be True (Bull and Bear, with Falsification Tests)

Bull case — what must be true for $56+ to be justified:

• Vishay 3.0 delivers a structural margin transformation — gross margin climbs durably from 19–22% toward the high-20s/31% target — and the German 12-inch fab fills at high utilization at accretive margins.
• AI/electrification/defense demand scales fast enough that revenue approaches the ~$5.5B 2028 target (a ~21% CAGR from $3.07B), absorbing the new capacity before the industry’s collective capacity floods the market.
• EBITDA roughly triples to ~$1.0B, free cash flow inflects clearly positive, and the market continues to award a premium (not just normal) multiple.
• Falsification test: gross margin stalls in the low-20s for several quarters, or book-to-bill rolls back below 1.0, or 2027 free cash flow is still negative — any one breaks the “structural transformation + early-cycle” thesis. The single cleanest tripwire: gross margin not crossing ~25% on a sustained basis by FY27.

Bear case — what must be true for the stock to mean-revert sharply:

• VSH remains a no-moat, price-taking, capital-intensive commodity maker; the recovery is an ordinary cyclical bounce; margins peak again in the high-20s at best and roll over with the cycle.
• The 2028 plan stays “delayed”; AI revenue stays a small minority of sales; capex keeps free cash flow negative; the multiple reverts toward the 4–12x decade EV/EBITDA band.
• At β≈2.0 with a –88% drawdown pedigree, the unwind of a crowded momentum trade is violent once the narrative cracks.
• Falsification test: a sustained multi-quarter march of gross margin through the mid-/high-20s with positive free cash flow and AI revenue scaling to a double-digit share of sales would prove the re-rate is earnings, not sentiment — and break the bear case.

Synthesis. The bull and bear cases pivot on the same variable — whether the Vishay 3.0 margin step-up is structural or cyclical — and the market at $56 has resolved that question entirely in the bull’s favor while management itself still calls the targets “delayed.” That asymmetry, not any doubt about the business surviving, is the heart of the call.

15. Source Appendix

See the accompanying Source Appendix (Appendix B in the combined report) for the full list of primary sources — SEC filings (FY2021–FY2025 10-Ks, Q1-26 10-Q, DEF 14A, Form 4 corpus, 8-K timeline), the Q1-26 earnings-call transcript, ROIC.ai fundamentals, AZI price/valuation/news data, and FactorsToday factor data — with access dates. Every non-obvious fact in this memo traces to an entry in the source appendix. Primary sources (SEC filings, transcripts) take precedence over third-party aggregated data, which is used for cross-checks and reconciled to the filings.

APPENDIX A — Standard Diligence Questionnaire

Vishay Intertechnology, Inc. (NYSE: VSH). Supplemental to the research memo. Fact / Interpretation / Assumption labeled where it matters. Grounded in the FY2025 10-K (filed 2026-02-13), Q1-26 10-Q, 2026 DEF 14A, Form 4 corpus, Q1-26 transcript, and ROIC/AZI/FactorsToday data.

General

What thoughtful questions have other investors asked? The live debates: (1) Is the Q1-26 inflection (book-to-bill 1.34) an early-innings multi-year up-cycle or a normal mid-cycle bounce? (2) Is “Vishay 3.0” a genuine margin transformation (toward the 31% gross-margin target) or a capital-destructive arms race that lifts EBITDA-margin while ROIC stays below WACC? (3) How real is the AI/data-center revenue (<$100M, <5% today) relative to the AI-driven re-rate? (4) When does free cash flow turn positive after three negative years? (5) Does the family-controlled board (~44% of votes) ever align incentives to capital returns?

Cyclicality & Earnings Nature

Cyclical high or low? A genuine trough, inflecting up. FY24/FY25 were the bottom (GAAP losses, 1.85% operating margin); Q1-26 is the early recovery (revenue +17% YoY). (Fact.) Today’s earnings are trough-level even as the stock is at a peak multiple. External environment or internal action? Predominantly external (the global electronic-components inventory cycle), with an internal overlay (Vishay 3.0 capacity, Nexperia share gains). (Interpretation.) Revenue stability? Low — transactional, ~56% through volatile distribution, no recurring/contracted revenue, cancellable backlog. Peak-to-trough revenue swing ~15% but earnings swing is violent (operating income fell 99% FY23→FY24) due to high fixed costs. (Fact.) Market size / direction? A flat-to-low-single-digit-growth, ASP-eroding global market; the secular kicker (electrification content/AI/defense) is real but partial. Revenue has gone nowhere on trend for a decade ($2.5–3.5B). (Fact/Interpretation.)

Business Quality & Competitive Moat

Industry more or less competitive? Structurally competitive and commoditized; consolidating among larger rivals, which Vishay tries to exploit as the “independent second-source.” (Fact.) How profitable (ROIC/ROE)? Peak ROIC ~17% (FY22), ~11% (FY23), negative (FY24/25); ROE distorted/meaningless. Even peak returns barely clear WACC. (Fact.) Industry profitability / barriers? Low margins, high capital intensity, many competitors (Infineon, onsemi, STMicro, Murata, TDK, Yageo, Diodes Inc., Littelfuse, Bourns, KOA, etc.); barriers are qualification/design-in cycles (real but shared among multiple qualified sources). (Fact.) Easily understood? Yes — a broad-line component manufacturer; the complexity is in segment-mix and the capacity bet, not the model. Undermined by low-cost labor? Partly — it competes against Asian passive leaders on cost and manufactures heavily in China/Taiwan itself (22,600 employees, ~6,900 in China). (Fact.) Do brands matter? Brands (Siliconix, Dale, Sprague, IHLP) carry reputation useful in qualification but not pricing power — ASPs erode ~1–3%/yr. (Interpretation.) Nature of competition? Price, availability/lead-time, qualification, breadth. A price-taker’s market. Switching costs? Real but narrow — auto/defense design-in qualification (12–24+ months) creates multi-year stickiness on certified parts, but customers deliberately multi-source, capping the benefit. (Fact/Interpretation.)

Financial Condition & Balance Sheet

Assets not fully on the balance sheet? Niche-leadership franchises (rectifiers, power-metal-strip resistors, wet-tantalum caps) and qualified design positions carry value beyond book. Owned fabs (Newport, Itzehoe, Taiwan, Italy) are on-balance-sheet. (Interpretation.) Off-balance-sheet liabilities? A/R securitization (~$125M sold receivables), operating-lease commitments (~$120M), $173M net pension/OPEB liability, ~$81M repatriation-tax accrual. (Fact.) How conservative is the accounting? Mixed — low SBC (~$22M, clean), but A/R securitization flatters operating cash flow (+$63M ≈ all of Q1-26 OCF), recurring ~$35M/yr inventory obsolescence, and a volatile >100% effective tax rate at trough. Read EBITDA skeptically. (Fact.) CapEx-hungry? Yes — extremely. Capex ~10–14% of revenue ($273M FY25, guided $400–440M FY26), ~1.3–2x depreciation; the defining feature of the financial profile. (Fact.)

Capital Allocation & Management

FCF generation / use / philosophy? Negative FCF (–$88M FY25, guided negative FY26); the “return ≥70% of FCF” policy is moot because FCF is negative. Cash is being deployed into the capacity build; the ~$54M/yr dividend is funded by borrowing. (Fact.) Significant acquisitions? Newport Wafer Fab (~$177M, 2024, from Nexperia) — a fixer-upper that was a margin drag for two years; serial acquirer historically. (Fact.) Buying back shares? Minimal — $12.5M FY25, $0 Q1-26; correctly throttled to ~zero as the stock tripled (no value-destructive high buybacks). No large opportunistic buyback at the bottom either. (Fact.) Issuing shares to insiders? Routine grants (~$22M SBC); no aggressive issuance. The $750M 2030 converts (strike $30.16) are a latent dilution claim (24.87M shares reserved; capped call exhausted above $43.98). (Fact.) Compensation policy? Red flag: no ROIC/ROE metric — pay is on adjusted-EBITDA-margin (30%) + adjusted-gross-margin (20%) + relative-TSR-vs-SOX. Pays management to grow margins/scale, not to earn returns on the $1.3B+ capex. To its credit, the FY25 EBITDA metric paid 0%. CEO total comp $10.34M (FY25). (Fact.) Motivations of management? Owner-operator-ish at the top (CEO/CFO/COO bought the bottom with personal cash) but family-controlled (~44.3% of votes via 10-vote Class B; Marc Zandman Exec Chairman took a $500K discretionary bonus in a loss year). (Fact/Interpretation.)

Valuation & Market Data

ADR / MLP / K-1? No — ordinary U.S. common stock (NYSE: VSH), $0.10 par. Dual-class (Class B 10-vote, family-held). Not a K-1 issuer. Dividend policy? ~$0.10/qtr (~$0.40/yr, ~0.7% yield); held flat; currently funded by borrowing. (Fact.) How profitable? Trough — near-breakeven operating, net losses FY24/25. (Fact.) Net income diverging from cash flow? Yes, and in both directions to watch: OCF exceeds (negative) net income, but free cash flow is negative and OCF is flattered by receivables securitization — the cleaner read (FCF) is worse than either GAAP earnings or OCF suggest. (Fact.)

Risks & Downside

What would cause the stock to decline? Mean-reversion from a richest-ever multiple (the dominant risk); a cyclical relapse (book-to-bill < 1.0); a margin-transformation failure; a narrative crack at β≈2.0. (Interpretation.) Catastrophic loss risk? Low — tangible asset base, niche franchises, compliant covenants, no maturities until 2028. Not a going-concern story. Total loss? Very low probability. The risk is valuation drawdown (potentially severe given β≈2.0 and –88% historical max drawdown), not impairment to zero. (Interpretation.)

Recent News & Events

Business environment changed? Yes — cyclical inflection (book-to-bill 1.34, backlog +21%), Nexperia share gains, AI-narrative crystallization, and the German fab equipping. (Fact.) Significant acquisitions / accounting changes? Newport (2024); new A/R securitization program (Q4-25); FY24 goodwill impairment ($66.5M) and restructuring ($40.6M). (Fact.) Recent changes — markets / facilities / management? New CFO (McConnell, Mar-2024); footprint restructuring (three site closures); 12-inch Itzehoe fab under construction; SiC product releases; SK Keyfoundry capacity partnership. (Fact.)

APPENDIX B — Source Appendix

Vishay Intertechnology, Inc. (NYSE: VSH). Primary sources take precedence over third-party aggregated data; aggregator figures are cross-checks reconciled to filings. Access date for all online sources: 2026-06-27 unless noted.

Primary — SEC filings (CIK 0000103730)

• FY2025 Form 10-K (filed 2026-02-13) — consolidated statements, Note 15 (segment & geographic/end-market revenue), Note 6 (debt / convertible notes), Note 1 (A/R securitization, revenue recognition), Note 11 (pension/OPEB), Note 19 (goodwill impairment), Item 1 (business, Vishay 3.0, competition, products), MD&A (capex, free-cash reconciliation, liquidity, tax). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000103730
• FY2021–FY2024 Form 10-Ks (filed 2022-02-23, 2023-02-22, 2024-02-16, 2025-02-14) — cycle history, prior-year reconciliations.
• Q1-2026 Form 10-Q (period ended 2026-04-04) — Q1-26 results, A/R securitization growth ($125.3M), revolver draw ($250M), covenant ratios, subsequent events.
• 2026 DEF 14A (proxy) — executive compensation metrics, dual-class structure, beneficial ownership (Zandman family ~44.3% of votes), say-on-pay.
• Form 4 corpus (2024–2026, 153 filings) — insider transactions; the May–June 2025 open-market purchase cluster (code P) by CEO Smejkal, CFO McConnell, COO Shoshani, EVPs and directors at $14.40–16.12; Zandman-family/director sales at higher 2023–25 prices.
• 8-K timeline (2024–2026) — Newport Wafer Fab acquisition; CFO transition (McConnell, eff. 2026-03-01); Sept-2024 restructuring; quarterly earnings/dividend declarations; convertible-note maturity (June-2025).

Primary — management commentary (treated as hypothesis, validated against filings)

• Q1-2026 earnings call transcript (2026-05-13) — book-to-bill 1.34, backlog +21% to $1.6B, Q2-26 guidance ($875–905M, GM ~22%), 2026 capex guide ($400–440M), negative-FCF guidance, AI exposure (<$100M FY25, “well above” FY26), Newport gross-profit-neutral, Nexperia share gains, SiC roadmap, capital-allocation Q&A. (Source: ROIC.ai transcript service; company IR at ir.vishay.com.)
• 2024 Investor/Analyst Day — 2023→2028 targets (revenue ~$5.5B, gross margin 31%, operating margin 20%, ~$5 EPS); referenced via the Q1-26 transcript Q&A and management framing.

Secondary / third-party — quantitative (cross-checks, reconciled to filings)

• ROIC.ai MCP — multi-year income statement, balance sheet, cash flow, profitability ratios (ROIC/ROE/margins), enterprise value, and the 10-year valuation-multiple series (EV/EBITDA, EV/sales, P/B, P/TBV, P/S history) used for own-history context. (Aggregated data; reconciled to the 10-K. Note: ROIC’s TTM EV snapshot was struck at a stale ~$18 market cap and was recomputed live at $56.35.)
• AZI (azitrading.com) — 5-year adjusted price/OHLCV CSV (price-action event map; 200-EMA ~$28; beta); valuation_index own-history percentiles (composite 99.3rd; P/B/P/S 99.4th; P/E percentile disregarded as a near-zero-EPS artifact); news feed (the “300% breakout” / “Is the rally over?” coverage). (Underlying articles cross-checked to primary sources.)
• FactorsToday (factorstoday.com) — factor loadings (Market β ~1.58–1.66 across models; realized β ~2.0; LowVol −0.80, SmallSize +0.77, Semiconductors/Technology sector betas), leaderboard (lifetime Sharpe 0.19, max drawdown −88%; de-annualized m3/m6 returns), stock-info (rs_12m +270%, alpha −0.09), related-stocks comp cross-check. (Third-party statistical estimates; facts reportable, “will continue/revert” treated as interpretation.)

Peer / industry references

• Same-sector peers used for industry framing and the valuation comp set: Advanced Energy (AEIS), Skyworks (SWKS), Vicor (VICR), MKS Instruments (MKSI), Silicon Motion (SIMO) — the “mediocre cyclical re-rated to richest-ever on the AI build-out” cohort.
• Public peer economics referenced for the competitive/valuation comparison: Infineon, ON Semiconductor (ON), STMicroelectronics, Texas Instruments (TXN), Analog Devices (ADI), Microchip (MCHP), Diodes Inc. (DIOD), Littelfuse (LFUS), Murata, TDK, Yageo — gross-margin and EV/EBITDA ranges per their public filings/standard industry data.

Every non-obvious fact in this note traces to one of the primary sources above.